Reliability of calcium-binding protein S100B measurement toward optimization of hyperosmolal therapy in Traumatic Brain Injury

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 4, 2013, Pages 477-485

  Hendoui, N ^a,b   Beigmohammadi, M T ^c   Mahmoodpoor, A ^d   Ahmadi, A ^c   Abdollahi, M ^b   Hasanpour, M ^e   Hadi, F ^f   Khazaeipour, Z ^g   Mousavi, S ^h   Mojtahedzadeh, M ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f ISLAMIC AZAD UNIVERSITY   (Iran)

^g TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hypertonic saline 5 ; Intracranial hypertension; Mannitol; Osmotherapy; S100B; Traumatic brain injury

Indexed keywords

CALCIUM BINDING PROTEIN; MANNITOL; PROTEIN S100B; SODIUM CHLORIDE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; FEMALE; GLASGOW COMA SCALE; HUMAN; HYPEROSMOLALITY; MALE; MEAN ARTERIAL PRESSURE; OSMOLALITY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SODIUM BLOOD LEVEL; TRAUMATIC BRAIN INJURY;

ADOLESCENT; ADULT; AGED; ARTERIAL PRESSURE; BIOLOGICAL MARKERS; BRAIN INJURIES; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; DIURETICS, OSMOTIC; FEMALE; GLASGOW COMA SCALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MANNITOL; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NERVE GROWTH FACTORS; ORGAN DYSFUNCTION SCORES; OSMOLAR CONCENTRATION; REPRODUCIBILITY OF RESULTS; S100 PROTEINS; SALINE SOLUTION, HYPERTONIC; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84878572176     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. LEÓN-CARRIÓN J, DOMÍNGUEZ-MORALES MDEL R, BARROSO Y MARTÍN J-M, MURILLO-CABEZAS F. Epidemiology of traumatic brain injury and subarachnoid hemorrhage. Pituitary 2005; 8: 197-202.
2. BRUNS J, JR, HAUSER WA. The epidemiology of traumatic brain injury: a review. Epilepsia 2003; 44: 2-10.
3. ZINK BJ, SZMYDYNGER-CHODOBSKA J, CHODOBSKI A. Emerging concepts in the pathophysiology of traumatic brain injury. Psychiat Clin North Am 2010; 33: 741-756.
4. WERNER C, ENGELHARD K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007; 99: 4-9.
5. BHARDWAJ A, ULATOWSKI JA. Hypertonic saline solutions in brain injury. Curr Opin Crit Care 2004; 10: 126-131.
6. BRAIN TRAUMA FOUNDATION; AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS; CONGRESS OF NEUROLOGICAL SURGEONS; JOINT SECTION ON NEUROTRAUMA AND CRITICAL CARE, AANS/CNS, BRATTON SL, CHESTNUT RM, GHAJAR J, MCCONNELL HAMMOND FF, HARRIS OA, HARTL R, MANLEY GT, NEMECEK A, NEWELL DW, ROSENTHAL G, SCHOUTEN J, SHUTTER L, TIMMONS SD, ULLMAN JS, VIDETTA W, WILBERGER JE, WRIGHT DW. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma 2007; 24(Suppl 1): S14-20. (DOUBLE)
7. OGDEN AT, MAYER SA, CONNOLLY JR ES. Hyperosmolar agents in neurosurgical practice: the evolving role of hypertonic saline.Neurosurgery 2005; 57: 207-215.
8. TIMMONS SD. Current trends in neurotrauma care. Crit Care Med 2010; 38: S431-S444.
9. BRAIN TRAUMA FOUNDATION; AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS; CONGRESS OF NEUROLOGICAL SURGEONS; JOINT SECTION ON NEUROTRAUMA AND CRITICAL CARE, AANS/CNS, BRATTON SL, CHESTNUT RM, GHAJAR J, MCCONNELL HAMMOND FF, HARRIS OA, HARTL R, MANLEY GT, NEMECEK A, NEWELL DW, ROSENTHAL G, SCHOUTEN J, SHUTTER L, TIMMONS SD, ULLMAN JS, VIDETTA W, WILBERGER JE, WRIGHT DW. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma 2007; 24(Suppl 1): S14-20.
10. SUAREZ JI. Hypertonic saline for cerebral edema and elevated intracranial pressure.Clev Clin J Med 2004; 71(Suppl 1): S9-13.
11. WHITE H, COOK D, VENKATESH B. The use of hypertonic saline for treating intracranial hypertension after traumatic brain injury. Anesth Analg 2006; 102: 183-146.
12. DOYLE JA, DAVIS DP. The use of hypertonic saline in the treatment of traumatic brain injury. J Trauma 2001; 50: 367-383.
13. WARE ML, NEMANI VM, MEEKER M, LEE C, MORABITO DJ, MANLEY GT. Effects of sodium chloride solution 23.4% in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study. Neurosurgery 2005; 57: 727-736.
14. HARUTJUNYAN L, HOLZ C, RIEGER A, MENZEL M, GROND S, SOUKUP J. Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients a randomized clinical trial [ISRCTN62699180]. Crit Care 2005; 9: R530-R540.
15. QURESHI AI, SUAREZ JI, BHARDWAJ A, MIRSKI M, SCHNITZER MS, HANLEY DF, ULATOWSKI JA. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain. Crit Care Med 1998; 26: 440-446.
16. QURESHI AI, SUAREZ JI, CASTRO A, BHARDWAJ A. Use of hypertonic saline/acetate infusion in treatment of cerebral edema in patients with head trauma: experience at a single center. J Trauma 1999; 47: 659-665.
17. MUNAR F, FERRER AM, DE NADAL M, POCA MA, PEDRAZA S, SAHUQUILLO J, GARNACHO A. Cerebral hemodynamic effects of 7.2% hypertonic saline in patients with head injury and raised intracranial pressure. J Neurotrauma 2000; 17: 41-51.
18. SCHWARZ S, GEORGIADIS D, ASCHOFF A, SCHWAB S. Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke 2002; 33: 136-140.
19. BENTSEN G, BREIVIK H, LUNDAR T, STUBHAUG A. Hypertonic saline (7.2%) in 6% hydroxyethyl starch reduces intracranial pressure and improves hemodynamics in a placebo-controlled study involving stable patients with subarachnoid hemorrhage. Crit Care Med 2006; 34: 2912-2917.
20. BATTISON C, ANDREWS PJ, GRAHAM C, PETTY T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 2005; 33: 196-202.
21. KAMEL H, NAVI BB, NAKAGAWA K, HEMPHILL III JC, KO NU. Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: A meta-analysis of randomized clinical trials. Crit Care Med 2011; 39: 554-559.
22. BLOOMFIELD SM, MCKINNEY J, SMITH L, BRISMAN J. Reliability of S100B in predicting severity of central nervous system injury. Neurocritic Care 2007; 6: 121-138.
23. QURESHI AI. Evaluation of brain injury using a blood test: is there a role in clinical practice? Crit Care Med 2002; 30: 2778-2779.
24. PELINKA LE, KROEPFL A, LEIXNERING M, BUCHINGER W, RAABE A, REDL H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004; 21: 1553-1561.
25. ROMNER B, INGEBRIGTSEN T, KONGSTAD P, BORGESEN SE. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma 2000; 17: 641-647.
26. BERGER RP, BEERS SR, RICHICHI R, WIESMAN D, ADELSON PD. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma 2007; 24: 1793-1801.
27. BAKER AJ, RHIND SG, MORRISON LJ, BLACK S, CRNKO NT, SHEK PN, RIZOLI SB. Resuscitation with hypertonic saline/dextran reduces serum biomarker levels and correlates with outcome in severe traumatic brain injury patients. J Neurotrauma 2009; 26: 1227-1240.
28. BRAIN TRAUMA FOUNDATION, AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS, CONGRESS OFNEUROLOGICAL SURGEONS, et al. Guidelines for the management of severe traumatic brain injury. J Neurotrauma 2007; 24: S1-S161.
29. KNAUS WA, DRAPER EA, WAGNER DP, ZIMMERMAN JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
30. VOSYLIUS S, SIPYLAITE J, IVASKEVICIUS J. Sequential Organ Failure Assessment Score as the determinant of outcome for patients with severe sepsis. Croat Med J 2004; 45: 715-720.
31. KLEINDIENST A, HESSE F, BULLOCK MR, BUCHFELDER M. The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 2007; 161: 317-325.
32. ROTHERMUNDT M, PETERS M, PREHN JH, AROLT V.S100B in brain damage and neurodegeneration. Microsc Res Technique 2003; 60: 614-632.
33. GONÇALVES CA, LEITE MC, NARDIN P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008; 41: 755-761.
34. ZIMMER DB, CORNWALL EH, LANDAR A, SONG W. The S100 protein family: history, function, and expression. Brain Res Bull 1995; 37: 417-429.
35. MORI T, TAN J, ARENDASH GW, KOYAMA N, NOJIMA Y, TOWN T. Overexpression of human S100B exacerbates brain damage and periinfarct gliosis after permanent focal ischemia. Stroke 2008; 39: 2114-2121.
36. REALI C, SCINTU F, PILLAI R, DONATO R, MICHETTI F, SOGOS F. S100b counteracts effects of the neurotoxicant trimethyltin on astrocytes and microglia. J Neurosci Res 2005; 81: 677-686.
37. HU J, FERREIRA A, VAN ELDIK L-J. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem 1997; 69: 2294-2301.
38. LAM AG, KOPPAL T, AKAMA KT, GUO L, CRAFT JM, SAMY B, SCHAVOCKY JP, WATTERSON D-M, VAN ELDIK LJ. Mechanism of glial activation by S100B: involvement of the transcription factor NFkappaB. Neurobiol Aging 2001; 22: 765-772.
39. RIZOLI SB, RHIND SG, SHEK PN, INABA K, FILIPS D, TIEN H, TIEN H, BRENNEMAN F, ROTSTEIN O. The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, doubleblinded trial. Ann Surg 2006; 243: 47-57.
40. VIALET R, ALBANESE J, THOMACHOT L, ANTONINI F, BOURGOUIN A, ALLIEZ B, MARTIN C. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med 2003; 31: 1683-1687.
41. FROELICH M, NI Q, WESS C, OUGORETS I, HERTL R. Continuous hypertonic saline therapy and the occurrence of complications in neurocritically ill patients. Crit Care Med 2009; 37: 1433-1441.
42. WEANT K-A, COOK A-M. Pharmacologic strategies for the treatment of elevated intracranial pressure: focus on osmotherapy. Adv Emerg Nurs J 2008; 30: 17-26.
43. SIMMA B, BURGER R, FALK M, SACHER P, FANCONI S. A prospective, randomized, and controlled study of fluid management in children with severe head injury: lactated Ringer's solution versus hypertonic saline. Crit Care Med 1998; 26: 1265-1270.
44. KHANNA S, DAVIS D, PETERSON B, FISHER B, TUNG H, O'QUIGLEY J, DEUTSCH R. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Crit Care Med 2000; 28: 1144-1151.
45. PETERSON B, KHANNA S, FISHER B, MARSHALL L. Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients. Crit Care Med 2000; 28: 1136-1143.
46. ZORNOW M-H, PROUGH D-S. Fluid management in patients with traumatic brain injury. New Horiz (Baltimore) 1995; 3: 488-498.
47. FRANCONY G, FAUVAGE B, FALCON D, CANET C, DILOU H, LAVAGNE P, JACQUOT C, PAYEN G-F. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Crit Care Med 2008; 36: 795-800.
48. ODDO M, LEVINE J, FRANGOS S. Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension. J Neurol Neurosurg Psychiatry 2009; 80: 916-920.
49. SCHWARZ S, GEORGIADIS D, ASCHOFF A, SCHWAB S. Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke 2002; 33: 136-140.
50. WAKAI A, ROBERTS I-G, SCHIERHOUT G. Mannitol for acute traumatic brain injury (Review). Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001049.